🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 23 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 06/03/2007 | 29,20 | 29,67 | 28,70 | 29,51 | +2,22% | 3,32% | 2.341.500 |
| 05/03/2007 | 29,21 | 30,05 | 28,81 | 28,87 | -2,00% | 4,25% | 1.952.700 |
| 02/03/2007 | 29,98 | 30,15 | 29,26 | 29,46 | -1,90% | 2,97% | 2.167.100 |
| 01/03/2007 | 30,36 | 30,53 | 29,55 | 30,03 | -2,15% | 3,23% | 2.172.500 |
| 28/02/2007 | 31,20 | 31,34 | 30,61 | 30,69 | -1,95% | 2,34% | 2.189.500 |
| 27/02/2007 | 31,20 | 31,85 | 31,13 | 31,30 | -1,01% | 2,31% | 2.488.400 |
| 26/02/2007 | 32,10 | 32,23 | 31,27 | 31,62 | -1,59% | 2,99% | 1.241.100 |
| 23/02/2007 | 32,30 | 32,97 | 32,10 | 32,13 | -0,62% | 2,69% | 2.129.600 |
| 22/02/2007 | 31,47 | 32,36 | 31,29 | 32,33 | +2,86% | 3,40% | 1.535.400 |
| 21/02/2007 | 31,35 | 31,52 | 31,05 | 31,43 | +0,03% | 1,50% | 1.179.900 |
| 20/02/2007 | 30,25 | 31,81 | 30,05 | 31,42 | +2,92% | 5,82% | 1.751.200 |
| 16/02/2007 | 31,42 | 31,66 | 30,38 | 30,53 | -3,23% | 4,07% | 1.826.100 |
| 15/02/2007 | 31,96 | 32,11 | 31,44 | 31,55 | -1,62% | 2,10% | 1.144.800 |
| 14/02/2007 | 31,36 | 32,26 | 31,36 | 32,07 | +1,91% | 2,87% | 1.320.400 |
| 13/02/2007 | 31,99 | 32,54 | 31,13 | 31,47 | -1,69% | 4,41% | 1.358.400 |
| 12/02/2007 | 32,20 | 32,23 | 31,65 | 32,01 | -1,08% | 1,80% | 893.100 |
| 09/02/2007 | 32,95 | 33,15 | 32,19 | 32,36 | -2,03% | 2,91% | 1.073.500 |
| 08/02/2007 | 33,13 | 33,34 | 32,73 | 33,03 | -0,15% | 1,84% | 935.300 |
| 07/02/2007 | 33,01 | 33,65 | 32,69 | 33,08 | -0,03% | 2,91% | 1.490.400 |
| 06/02/2007 | 32,70 | 33,13 | 32,23 | 33,09 | +1,75% | 2,75% | 1.590.400 |
| 05/02/2007 | 33,60 | 33,60 | 32,44 | 32,52 | -3,59% | 3,45% | 2.055.500 |
| 02/02/2007 | 35,12 | 35,13 | 33,69 | 33,73 | -3,07% | 4,10% | 2.422.300 |
| 01/02/2007 | 35,23 | 35,55 | 34,21 | 34,80 | -1,56% | 3,80% | 1.604.800 |
| 31/01/2007 | 35,67 | 35,81 | 34,89 | 35,35 | -1,20% | 2,58% | 1.544.200 |
| 30/01/2007 | 35,40 | 35,92 | 35,18 | 35,78 | +1,33% | 2,09% | 1.164.800 |
| 29/01/2007 | 34,80 | 35,57 | 34,73 | 35,31 | +0,80% | 2,41% | 1.391.100 |
| 26/01/2007 | 35,09 | 35,17 | 34,24 | 35,03 | -0,03% | 2,65% | 1.626.400 |
| 25/01/2007 | 36,16 | 36,21 | 34,62 | 35,04 | -3,39% | 4,40% | 1.937.900 |
| 24/01/2007 | 36,17 | 36,61 | 36,00 | 36,27 | +0,11% | 1,69% | 983.400 |
| 23/01/2007 | 35,89 | 36,27 | 35,66 | 36,23 | +0,78% | 1,70% | 2.549.100 |